Biosimilars Market Overview by Business Manufactures with Forecast Analysis with Key Players Novartis, Synthon Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon and More
This report provides a comprehensive market share analysis of leading companies and highlights the competition in the market. Product launch is the key strategy adopted by the leading player of biosimilars industry. The key companies profiled in this report are Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec, Inc., and Genentech (Roche Group).
Download Sample PDF Brochure of Biosimilars Market Study at : https://www.alliedmarketresearch.com/request-sample/700
Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Regulations for biosimilars play a vital role in maintaining the viability and balance between original and biosimilars products. Various regulatory authorities such as EMA and FDA actively regulate the biosimilars commercialization and development.
The market is driven by factors such rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs, especially for the high priced patented drugs.
However, the market growth is limited by the high cost of reference products increases the financial burden on patients as well as reimbursement service providers. The lack in economies of scale due to lower demand is a factor that results in these high costs.
Furthermore, the growth of the biosimilars market is hampered due to the lack of regulatory guidelines, consumers brand preferences, reluctance of physicians to prescribed biosimilars and the high capital required for research and development. Countries from the European Union presently dominate the market owing to the favorable government regulations in this region. North America biosimilars market is currently witnessing restrictions due to the flexible and ineffective regulations.
The product segment in the biosimilars market comprises of Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Colony Stimulating Factors and others. The biosimilars applications market is segmented into blood disorders, oncology diseases, chronic and autoimmune diseases and growth hormone deficiency. The application of biosimilars in blood disease treatment is the highest revenue generating segment owing to the high-priced reference biologics and frequent application.
Do purchase Enquiry at : https://www.alliedmarketresearch.com/purchase-enquiry/700
However, biosimilars applications in autoimmune and chronic diseases exhibit the highest potential due to the changing off patent scenario. Biopharmaceutical industry is vastly dependent on the advanced technologies used in various procedures of development and manufacturing. These technologies are acting as a mandate for every single operation in biopharmaceutical and healthcare research industry.
Some of the significant technologies are discussed in the report includes, Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA technology), Nuclear magnetic resonance (NMR) technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting and Bioassay. Monoclonal antibody technology and bioassay technologies are the most significant technologies used in biosimilar development and validation.
Based on geography, the biosimilars market is segmented across North America, Europe, Asia-Pacific and LAMEA. Asia Pacific and LAMEA exhibit a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions
The Global biosimilars products market is segmented into Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, G-CSF, peptide and other biosimilars. Patent expiration is a key factor that largely influences the biosimilars market. Most of the blockbuster patents would expire by the end of 2014; a factor that would provide competitive advantage to local pharmaceutical manufacturers over global players.
Biosimilars/follow-on-biologics Market Key Benefits
• This report provides a detailed analysis of drivers and factors that limit the market expansion.
• The report provides market forecast for the next eight years by considering the 2014 as the base year for evaluation.
• Comprehensive and quantitative data about changing market trends, competition and opportunities in biosimilars market are provided in the report.
• Porters Five Forces model and SWOT analysis would help stakeholders in making strategic decisions.
• Deep dive analysis of leading market players and their key strategies, helps in better understanding the market dynamics.
• Identification of key investment pockets in the biosimilars market would help the stakeholders in making informed decisions.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Overview by Business Manufactures with Forecast Analysis with Key Players Novartis, Synthon Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon and More here
News-ID: 1595401 • Views: 508
More Releases from Allied Market Research
Drug Screening Laboratory Services Market Share Size, Statistics, Demand, Revenu …
Drug Screening Laboratory Services Market by Service type, (Workplace Drug Testing and Clinical Toxicology Testing), Sample Type (Urine, Oral Fluid, Hair and Others), End User (Retail, Oil & Gas, Transportation, Staffing, Government, Other Workplace, Hospital Laboratories, Clinical Laboratories, and Other Laboratories): Global Opportunity Analysis and Industry Forecast, 2020-2027 by Service type, (Workplace Drug Testing and Clinical Toxicology Testing), Sample Type (Urine, Oral Fluid, Hair and Others), End User (Retail, Oil
Orthopedic Devices Market Global Growth, Current Scenario Technology Trends, Com …
Rise in geriatric population and increase in chronic diseases related to orthopedics such as osteoarthritis, traumatic fractures, osteopenia, and others are play a major role in the growth of the orthopedic device market. In addition, various growth opportunities such as surge in healthcare infrastructure, increase in affordability, and rise in awareness related to orthopedic conditions in emerging economies are expected to boost the market growth in the coming years. Download Free
Neurosurgery Devices Market: Global Trends, Segmentation and Opportunities Forec …
Neurosurgery devicesare devices that help in prevention, treatment, and diagnosis of conditions and disorders associated with nervous system mainly the brain, spinal cord, peripheral nerves, and extra-cranial cerebrovascular system. The neurological conditions include dementia, headache disorders, neuro-infections, and multiple sclerosis, traumatic brain injuries, pain associated with neurological disorders, neurological disorders associated with malnutrition, stroke, epilepsy and Parkinson’s disease.These disorders are fatal and cannot be cured by therapeutics. Some of the
COVID-19 Impact on Nerve Repair and Regeneration Market Global Industry Size, Sh …
Global Nerve Repair and Regeneration Market are expected to reach $13,938 million by 2023, growing at a CAGR of 13.0 % during the forecast period, 2019-2023. The factors propelling the nerve repair and regeneration market are rise in geriatric population, growing prevalence of neurological and epidemic disorders, and introduction of novel and innovative products for nerve repair and regeneration. However, stringent regulatory requirements for product approvals, lack of skilled professionals, and
More Releases for Biosimilars
PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on